Učitavanje...

Safety and Tolerability of PD‐1/PD‐L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta‐Analysis

BACKGROUND. Compared with chemotherapy, significant improvement in survival outcomes with the programmed death receptor‐1 (PD‐1) inhibitors nivolumab and pembrolizumab and the programmed death‐ligand 1 (PD‐L1) inhibitor atezolizumab has been shown in several types of advanced solid tumors. We conduc...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncologist
Glavni autori: Nishijima, Tomohiro F., Shachar, Shlomit S., Nyrop, Kirsten A., Muss, Hyman B.
Format: Artigo
Jezik:Inglês
Izdano: AlphaMed Press 2017
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5388381/
https://ncbi.nlm.nih.gov/pubmed/28275115
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0419
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!